trending Market Intelligence /marketintelligence/en/news-insights/trending/oOq5vYqCO1U4cG-vkyNfew2 content esgSubNav
In This List

Eisai cancer drug approved as 1st-line treatment in Japan

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Eisai cancer drug approved as 1st-line treatment in Japan

Eisai Co. Ltd. said Treakisym was approved as a first-line treatment in Japan for patients with low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma, or MCL, a cancer of white blood cells.

The drug will be used in combination with rituximab to treat patients. It is already approved as a monotherapy for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma and MCL.

Eisai began marketing Treakisym in late-2010 as part of a licensing agreement with SymBio Pharmaceuticals Ltd.